IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) is proud to announce the successful completion of a single-site study utilizing the ProSense® System, a minimally-invasive cryoablation technology for destroying tumors without having to resort to surgical tumor removal.
The study, led by Dr. Francois H. Cornelis, MD, PhD, of the Sorbonne University Department of Interventional Radiology and Oncology at Tenon Hospital in Paris, France, was recently published in the Journal of Vascular and Interventional Radiology and was titled “Pain-Free Survival After Percutaneous Image-Guided Cryoablation of Extraperitoneal Endometriosis.”
Dr. Cornelis also presented the study data at the Society of Interventional Radiology 2023 Annual Scientific Meeting on March 8, 2023. IceCure is thrilled to have been a part of this groundbreaking research, and looks forward to continuing to provide innovative solutions that can improve patient care and outcomes.
Cryoablation, a minimally invasive and image-guided procedure, has been used to treat abdominal wall endometriosis and its associated symptoms with satisfactory results and low morbidity. A recent study conducted to evaluate the pain-free survival of cryoablation for symptomatic extraperitoneal endometriosis (EE) included 42 patients who were treated with either IceCure’s ProSense cryoprobe or Varian’s V-probe.
The results were promising, showing that cryoablation could be a viable alternative to surgical excision and hormonal agents. Patients were made aware that if cryoablation failed, a surgical procedure may be necessary.
Percutaneous cryoablation has been proven to be a safe and effective procedure for reducing pain and achieving local control of EE. With a median follow-up of 13.5 months after the procedure, this study demonstrated significant results in terms of pain reduction and local control. The findings from this study indicate that cryoablation is a viable option for treating EE and should be considered as an effective treatment option.
Cryoablation proved to be a highly effective solution, successfully avoiding secondary surgery in 92.8% of patients and 93.6% of treated nodules. An impressive success rate that offers hope to those looking for an alternative to more invasive treatments.
Pain-free survival rates remained impressively high, with 93.75% of patients surviving after 6 months, and an impressive 82.72% surviving after 12 months, 24 months, and 36 months.
At the last follow-up, pain decreased from a median of 8/10 on the visual analogue scale to a remarkable 0/10 (P < 0.0001). This is a remarkable improvement, and demonstrates the efficacy of the treatment.
Four patients experienced an adverse event in the days after their procedure, with one patient suffering a severe reaction.
IceCure Medical is proud to have been part of an independent study conducted by Dr. Cornelis and the team of doctors at Sorbonne University and Tenon Hospital, which found cryoablation to be an effective minimally invasive treatment for endometriosis.
Tenon Hospital is highly esteemed in the field of gynecology and interventional radiology, and this study has further demonstrated the value of the ProSense system, which is already FDA-cleared for use as a cryosurgical tool in gynecology. We hope that this evidence will help provide patients with more options for treating this debilitating and painful condition.
Endometriosis is an often overlooked, yet highly prevalent chronic condition impacting an estimated 190 million women of reproductive age worldwide. Characterized by severe, life-impacting symptoms, individuals suffering from endometriosis often face an extensive delay between the onset of symptoms and a diagnosis.
Despite the wide prevalence of this condition, current treatments are primarily focused on symptom control. Endometriosis is often incidentally observed on surgical scars in women with or without a history of the condition.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) (TASE: ICCM) is revolutionizing cancer treatment with their innovative ProSense® cryoablation therapy. This minimally invasive procedure uses liquid nitrogen to freeze tumors (benign and cancerous) in areas such as breast, kidney, bone, and lung. Easily performed in a relatively short procedure, it offers a safe and effective alternative to hospital surgical tumor removal, and is now available in the U.S., Europe, and China.